Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$3.50 +20.3%	$2.15	$1.38 ▼ $19.69	$74.10M	1.48	580,925 shs	3.18 million shs
BCRX BioCryst Pharmaceuticals	$10.34 +3.7%	$7.92	$5.34 ▼ $11.11	$2.16B	1.08	2.99 million shs	5.56 million shs
NVAX Novavax	$6.34 +6.2%	$6.83	$5.01 ▼ $23.86	$1.02B	3.21	7.91 million shs	10.24 million shs
SGMO Sangamo Therapeutics	$0.75 +7.1%	$0.78	$0.30 ▼ $3.18	$171.90M	1.46	8.60 million shs	4.63 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+19.45%	+13.27%	+105.88%	+9.03%	-66.63%
BCRX BioCryst Pharmaceuticals	+3.61%	-6.26%	+51.61%	+15.02%	+94.36%
NVAX Novavax	+5.84%	+1.12%	+8.19%	-21.53%	-28.60%
SGMO Sangamo Therapeutics	+7.14%	+4.17%	+4.38%	-34.21%	+33.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGEN Agenus	3.7106 of 5 stars	3.1	1.0	4.6	3.0	1.7	0.6
BCRX BioCryst Pharmaceuticals	4.5077 of 5 stars	4.4	2.0	4.2	3.3	1.7	0.6
NVAX Novavax	3.6708 of 5 stars	3.2	1.0	4.7	3.1	0.8	0.6
SGMO Sangamo Therapeutics	1.6129 of 5 stars	3.3	1.0	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.17	Hold	$8.75	150.00% Upside
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	60.11% Upside
NVAX Novavax	2.43	Hold	$19.00	199.68% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$5.17	588.89% Upside

Current Analyst Ratings Breakdown

Latest AGEN, NVAX, SGMO, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/30/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
4/29/2025	BCRX BioCryst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
4/21/2025	AGEN Agenus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/11/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $11.00
4/10/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$103.46M	0.72	N/A	N/A	($7.78) per share	-0.45
BCRX BioCryst Pharmaceuticals	$503.49M	4.30	N/A	N/A	($2.22) per share	-4.66
NVAX Novavax	$682.16M	1.49	N/A	N/A	($6.04) per share	-1.05
SGMO Sangamo Therapeutics	$57.80M	2.97	$0.02 per share	30.42	$0.47 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	-$245.76M	-$10.68	N/A	N/A	N/A	-145.89%	N/A	-85.68%	N/A
BCRX BioCryst Pharmaceuticals	-$226.54M	-$0.26	N/A	N/A	N/A	-30.01%	N/A	-24.06%	N/A
NVAX Novavax	-$545.06M	$2.65	N/A	79.25	2.85	-32.18%	N/A	-17.05%	N/A
SGMO Sangamo Therapeutics	-$257.83M	-$0.52	N/A	N/A	N/A	-257.87%	-264.16%	-107.24%	N/A

Latest AGEN, NVAX, SGMO, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AGEN Agenus	-$1.61	-$1.03	+$0.58	-$1.03	$26.38 million	$24.07 million
5/9/2025	Q1 2025	NVAX Novavax	$0.19	$2.93	+$2.74	$2.93	$204.08 million	$666.66 million
5/8/2025	Q1 2025	SGMO Sangamo Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	$7.90 million	N/A
3/17/2025	Q4 2024	SGMO Sangamo Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	$11.70 million	$7.55 million
3/11/2025	Q4 2024	AGEN Agenus	-$2.36	-$2.04	+$0.32	-$2.04	$30.09 million	$26.84 million
2/27/2025	Q4 2024	NVAX Novavax	-$0.75	-$0.51	+$0.24	-$0.51	$85.48 million	$88.31 million
2/24/2025	Q4 2024	BCRX BioCryst Pharmaceuticals	-$0.07	-$0.13	-$0.06	-$0.13	$126.64 million	$131.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.19	0.19
BCRX BioCryst Pharmaceuticals	N/A	2.78	2.73
NVAX Novavax	N/A	0.93	0.93
SGMO Sangamo Therapeutics	N/A	1.35	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
BCRX BioCryst Pharmaceuticals	85.88%
NVAX Novavax	53.04%
SGMO Sangamo Therapeutics	56.93%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	4.60%
BCRX BioCryst Pharmaceuticals	4.80%
NVAX Novavax	1.00%
SGMO Sangamo Therapeutics	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	440	21.17 million	22.38 million	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	197.19 million	Optionable
NVAX Novavax	1,990	160.84 million	158.58 million	Optionable
SGMO Sangamo Therapeutics	480	229.19 million	202.81 million	Optionable

AGEN, NVAX, SGMO, and BCRX Headlines

Recent News About These Companies

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12 at 10:06 PM | seekingalpha.com

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 12 at 7:17 PM | finance.yahoo.com

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

May 12 at 6:55 PM | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12 at 6:26 PM | businesswire.com

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12 at 6:23 PM | businesswire.com

Sangamo Therapeutics Q1 2025 Earnings Preview

May 12 at 1:36 AM | msn.com

Why Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 5.70%

May 10 at 1:49 AM | aaii.com

Schonfeld Strategic Advisors LLC Purchases Shares of 1,709,615 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

May 8, 2025 | marketbeat.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $5.17 Average Price Target from Analysts

May 8, 2025 | americanbankingnews.com

Sangamo Therapeutics Sets Sights on 2026 BLA Filing for Fabry Disease Gene Therapy

May 7, 2025 | precisionmedicineonline.com

Sangamo Therapeutics (SGMO) Projected to Post Quarterly Earnings on Thursday

May 7, 2025 | americanbankingnews.com

Marshall Wace LLP Has $344,000 Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

May 7, 2025 | marketbeat.com

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

May 7, 2025 | finance.yahoo.com

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025 | businesswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 6, 2025 | marketbeat.com

740,000 Shares in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Acquired by Acuta Capital Partners LLC

May 4, 2025 | marketbeat.com

Boothbay Fund Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

May 3, 2025 | marketbeat.com

Sangamo Therapeutics (SGMO) Expected to Announce Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

May 1, 2025 | zacks.com

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

April 28, 2025 | businesswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Renaissance Technologies LLC

April 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
DoorDash’s Uptrend Is Gaining Momentum in 2025
By Thomas Hughes | May 9, 2025
View DoorDash’s Uptrend Is Gaining Momentum in 2025
IBM's AI Offensive: Assessing IBM's Path to Renewed Growth
By Jeffrey Neal Johnson | May 8, 2025
View IBM's AI Offensive: Assessing IBM's Path to Renewed Growth

AGEN, NVAX, SGMO, and BCRX Company Descriptions

Agenus NASDAQ:AGEN

$3.50 +0.59 (+20.27%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$3.66 +0.16 (+4.54%)

As of 04:17 AM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

BioCryst Pharmaceuticals NASDAQ:BCRX

$10.34 +0.37 (+3.71%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$10.44 +0.10 (+0.97%)

As of 04:45 AM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Novavax NASDAQ:NVAX

$6.34 +0.37 (+6.20%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$6.26 -0.08 (-1.18%)

As of 04:58 AM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sangamo Therapeutics NASDAQ:SGMO

$0.75 +0.05 (+7.11%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$0.46 -0.29 (-38.27%)

As of 04:58 AM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time